Skip to main content
Amplyx, Novartis enter licensing deal for potential antiviral drug

Amplyx Pharmaceuticals has acquired international rights from Novartis for MAU868, a new experimental compound being developed to target a protein linked to BK viral disease, which causes life-threatening infections in patients who have undergone stem cell or kidney transplants. No financial details regarding the deal were disclosed.

Full Story: